#China #Shanghai #HuaMedicine #HuaTangNing #Dorzagliatin

Hua Medicine Announces Impressive Interim Results for 2025

Hua Medicine has recently unveiled its interim results for the first half of 2025, reporting impressive growth and significant milestones achieved in their product commercialization. The company’s key product, HuaTangNing (华堂宁®), which is based on dorzagliatin, has witnessed remarkable sales growth, with an increase of 108% in year-on-year sales and 112% in net sales. The company's strategy of expanding reimbursement coverage continues to show positive impacts, resulting in a surge of prescription volumes across Tier 2 and Tier 3 hospitals. This success is attributed to the company’s comprehensive commercialization strategy, which has started yielding substantial results.

Following the termination of the exclusive promotional agreement with Bayer, Hua Medicine experienced a significant one-time recognition of deferred income amounting to RMB 1,243.5 million, leading the company to achieve a profit of approximately RMB 1,183.9 million for the first half of the year. This marks a crucial milestone as it represents the company's first profit during the performance period.

A notable highlight is the real-world study known as BLOOM, which involved 80 centers and 2,000 patients with Type 2 diabetes across China. This study confirmed the broad applicability and safety of dorzagliatin, strengthening the company’s position in the diabetes treatment field. The anticipation continues to grow as a registration application for Dorzagliatin 75mg (branded as MYHOMSIS®, 華領片TM) has been submitted in Hong Kong, aiming to extend the product’s reach throughout Greater China and into Southeast Asia.

Hua Medicine has also significantly improved its gross profit margin, which now stands at an impressive 54.2%, up from 46.5% during the same timeframe last year. This increase reflects the company’s focus on optimizing operational efficiency and production scale in line with its growing demand dynamics.

During the reporting period, the company enjoyed heightened financial performance alongside its operational advancements. The commercialization transformation has proven to be immensely successful, as sales of HuaTangNing reached 1,764,000 packs, underscoring the effectiveness of the newly established independent sales team.

Dr. Li Chen, the founder and CEO of Hua Medicine, articulated the transformative period of the first half of 2025. He remarked, "Our transition to fully manage the commercialization of HuaTangNing has ushered in double-digit growth in both sales and revenues, validating our innovative business model. The new drug application in Hong Kong signifies a pivotal step towards expanding our market presence beyond China into Southeast Asia and globally."

The company has consistently focused on diabetes and related metabolic diseases, fostering innovation through robust research and market expansion to better serve patients. With several ongoing clinical research initiatives, Hua Medicine is deepening its understanding of dorzagliatin’s long-term safety and effectiveness across diverse patient populations.

Real-world data continues to support dorzagliatin’s potential as a disease-modifying therapy. Hua Medicine presented new insights at the 2025 American Diabetes Association conference, showcasing dorzagliatin's mechanisms and novel therapeutic applications.

The future outlook for Hua Medicine appears vastly promising, with pipelines extending to new treatments and drug combinations. The company is working on a fixed-dose combination therapy of metformin and dorzagliatin, aimed at patients struggling with blood glucose control when using high doses of metformin. The pre-IND submission for this combination has already been achieved, with plans to initiate a bioequivalence study in early 2026.

Moreover, the company is expanding its partnership with premier international research institutions, fostering innovations through collaborative research initiatives. A Phase I trial sponsored by the University of Pennsylvania, assessing dorzagliatin for cystic fibrosis-related diabetes, has also received approval from the U.S. FDA, marking another achievement for Hua Medicine in its dedication to advancing diabetes care.

As the company looks to the future, it remains committed to its vision of improving health outcomes worldwide while emphasizing technological innovation and strategic collaborations across various metabolic disorders. The progressive efforts in enhancing digital engagement and utilizing AI capabilities reflect Hua Medicine's ambition of modernizing diabetes care and prolonging healthy life spans for patients globally.

In summary, Hua Medicine's impressive interim results not only highlight the effectiveness of its products but also illuminate the company's transformative growth strategies in the competitive pharmaceutical landscape. With a firm emphasis on innovation and market expansion, Hua Medicine is poised to become a leading entity in diabetes and metabolic disease management for years to come.